Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anil Koul

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
FEMS Microbiology Letters|April 21, 2010
Respiratory ATP synthesis: the new generation of mycobacterial drug targets?Dirk Bald, Anil Koul
Future Medicinal Chemistry|March 24, 2011
Respiratory syncytial virus: a prioritized or neglected target?Dirk Roymans, Anil Koul
Drug Discovery Today|October 4, 2012
Advances and strategies in discovery of new antibacterials for combating metabolically resting bacteriaDirk Bald, Anil Koul
Mbio|April 13, 2017
Targeting Energy Metabolism in <i>Mycobacterium tuberculosis</i>, a New Paradigm in Antimycobacterial Drug DiscoveryDirk Bald, Cristina Villellas, Ping Lu, et al.
Nature Reviews. Microbiology|April 15, 2004
Interplay between mycobacteria and host signalling pathwaysAnil Koul, Thomas Herget, Bert Klebl, et al.
Nature|January 29, 2011
The challenge of new drug discovery for tuberculosisAnil Koul, Eric Arnoult, Nacer Lounis, et al.
The Journal of Antibiotics|June 12, 2014
The ATP synthase inhibitor bedaquiline interferes with small-molecule efflux in Mycobacterium smegmatisPing Lu, Cristina Villellas, Anil Koul, et al.
Microbiology (Reading, England)|August 10, 2001
Serine/threonine protein kinases PknF and PknG of Mycobacterium tuberculosis: characterization and localizationAnil Koul, Axel Choidas, Anil K Tyagi, et al.
Nature|January 22, 2010
Essentiality of FASII pathway for Staphylococcus aureusWendy Balemans, Nacer Lounis, Ron Gilissen, et al.
Human Genetics|March 29, 2007
PGC-1alpha Thr394Thr and Gly482Ser variants are significantly associated with T2DM in two North Indian populations: a replicate case-control studyAudesh Bhat, Anil Koul, Ekta Rai, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
FEMS Microbiology Letters|April 21, 2010
Respiratory ATP synthesis: the new generation of mycobacterial drug targets?Dirk Bald, Anil Koul
Future Medicinal Chemistry|March 24, 2011
Respiratory syncytial virus: a prioritized or neglected target?Dirk Roymans, Anil Koul
Drug Discovery Today|October 4, 2012
Advances and strategies in discovery of new antibacterials for combating metabolically resting bacteriaDirk Bald, Anil Koul
Mbio|April 13, 2017
Targeting Energy Metabolism in <i>Mycobacterium tuberculosis</i>, a New Paradigm in Antimycobacterial Drug DiscoveryDirk Bald, Cristina Villellas, Ping Lu, et al.
Nature Reviews. Microbiology|April 15, 2004
Interplay between mycobacteria and host signalling pathwaysAnil Koul, Thomas Herget, Bert Klebl, et al.
Nature|January 29, 2011
The challenge of new drug discovery for tuberculosisAnil Koul, Eric Arnoult, Nacer Lounis, et al.
The Journal of Antibiotics|June 12, 2014
The ATP synthase inhibitor bedaquiline interferes with small-molecule efflux in Mycobacterium smegmatisPing Lu, Cristina Villellas, Anil Koul, et al.
Microbiology (Reading, England)|August 10, 2001
Serine/threonine protein kinases PknF and PknG of Mycobacterium tuberculosis: characterization and localizationAnil Koul, Axel Choidas, Anil K Tyagi, et al.
Nature|January 22, 2010
Essentiality of FASII pathway for Staphylococcus aureusWendy Balemans, Nacer Lounis, Ron Gilissen, et al.
Human Genetics|March 29, 2007
PGC-1alpha Thr394Thr and Gly482Ser variants are significantly associated with T2DM in two North Indian populations: a replicate case-control studyAudesh Bhat, Anil Koul, Ekta Rai, et al.
Pageof 5